Expertise in
3
conditions

Dr. Milton Fort

Oncology
Office
7515 Jefferson Hwy, 
Baton Rouge, LA 
Expertise in
3
conditions
Office
7515 Jefferson Hwy, 
Baton Rouge, LA 

Overview

Milton Fort is an Oncologist in Baton Rouge, Louisiana. Dr. Fort is highly rated in 3 conditions, according to our data. His top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Cancer, Ovarian Cancer, Lymphadenectomy, and Hysterectomy.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in LA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN

Locations

Office
7515 Jefferson Hwy, Baton Rouge, LA 70806

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
Enrollment Status: Unknown
Publish Date: December 29, 2021
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Expertise in
14
conditions
Dr. Shaista Faruqui
Oncology
Expertise in
14
conditions
Dr. Shaista Faruqui
Oncology

Shaista H. Faruqui M.D. Apmc

5320 Dijon Dr, 
Baton Rouge, LA 
 (8.1 miles away)
225-769-2161
Languages Spoken:
English
See accepted insurances

Shaista Faruqui is an Oncologist in Baton Rouge, Louisiana. Dr. Faruqui is highly rated in 14 conditions, according to our data. Her top areas of expertise are Idiopathic Neutropenia, Chronic Familial Neutropenia, Adult Immune Thrombocytopenia, and Immune Thrombocytopenic Purpura (ITP).

Expertise in
31
conditions
Dr. Hana Safah
Oncology
Expertise in
31
conditions
Dr. Hana Safah
Oncology

Office

7777 Hennessy Blvd Ste 212, 
Baton Rouge, LA 
 (9.7 miles away)
225-374-0320
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hana Safah is an Oncologist in Baton Rouge, Louisiana. Dr. Safah is highly rated in 31 conditions, according to our data. Her top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
60
conditions
Dr. Siva Sankar
Hematology | Oncology
Expertise in
60
conditions
Dr. Siva Sankar
Hematology | Oncology

Hematology Oncology Associates Of Baton Rouge

4950 Essen Ln, 
Baton Rouge, LA 
 (7.7 miles away)
225-767-0847
Languages Spoken:
English
See accepted insurances

Siva Sankar is a Hematologist and an Oncologist in Baton Rouge, Louisiana. Dr. Sankar is highly rated in 60 conditions, according to our data. His top areas of expertise are Thrombocytopenia, Sickle Cell Disease, Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Milton Fort

How do I make an appointment with Dr. Milton Fort?

You can book an appointment with Dr. Milton Fort by calling their office at 225-335-5892. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Milton Fort a top-rated expert for Malignant Mixed Mullerian Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Milton Fort is classified as an Advanced expert for Malignant Mixed Mullerian Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Milton Fort specialize in?

While Dr. Milton Fort is a Oncology, they have specific expertise in Malignant Mixed Mullerian Tumor, Endometrial Cancer, and Ovarian Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Milton Fort accept my insurance?

Dr. Milton Fort accepts most major insurance plans, including Louisiana Healthcare Connections. We recommend calling the office directly at 225-335-5892 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fort's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile